We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.66B
AUM Growth
-$158M
Cap. Flow
-$17.9M
Cap. Flow %
-1.08%
Top 10 Hldgs %
76.19%
Holding
43
New
1
Increased
5
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.4M
2
AZN icon
AstraZeneca
AZN
+$11.7M
3
ALKS icon
Alkermes
ALKS
+$2.9M
4
FOLD
Amicus Therapeutics
FOLD
+$1.14M
5
SAGE
Sage Therapeutics
SAGE
+$799K

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$17.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$17.4M
3
ABMD
Abiomed Inc
ABMD
+$11.6M
4
PRTA icon
Prothena Corp
PRTA
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
2 Financials 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$179M 10.8%
549,820
-34,113
-6% -$11.6M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$13.5B
$171M 10.32%
2,212,950
– –
INSM icon
3
Insmed
INSM
$29B
$166M 10.01%
6,019,106
– –
STAA icon
4
STAAR Surgical
STAA
$1.24B
$147M 8.85%
1,140,511
-127,300
-10% -$17.8M
UTHR icon
5
United Therapeutics
UTHR
$22.1B
$127M 7.66%
687,206
– –
PRTA icon
6
Prothena Corp
PRTA
$473M
$120M 7.25%
1,685,282
-46,200
-3% -$2.87M
BIIB icon
7
Biogen
BIIB
$30.1B
$102M 6.18%
361,600
– –
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$96.6M 5.83%
10,114,043
+111,600
+1% +$1.14M
RVNC
9
DELISTED
Revance Therapeutics, Inc.
RVNC
$89.2M 5.38%
3,201,866
– –
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$298M
$65M 3.92%
3,791,805
– –
EHTH icon
11
eHealth
EHTH
$39.1M
$46.4M 2.8%
1,145,870
– –
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$5.07B
$38.8M 2.34%
2,337,877
– –
ALGN icon
13
Align Technology
ALGN
$12.3B
$36.9M 2.23%
55,405
– –
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$35.1M 2.12%
6,856,513
– –
KPTI icon
15
Karyopharm Therapeutics
KPTI
$47.6M
$31.3M 1.89%
358,870
– –
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$27.4M 1.65%
617,930
+17,430
+3% +$799K
GRTS
17
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$25.4M 1.54%
2,356,282
– –
GOSS icon
18
Gossamer Bio
GOSS
$88.9M
$22.3M 1.35%
1,772,950
– –
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$20M 1.21%
4,484,411
– –
ALKS icon
20
Alkermes
ALKS
$8.26B
$18.2M 1.1%
589,900
+102,800
+21% +$2.9M
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$17.3M 1.04%
855,713
+523,000
+157% +$14.4M
AZN icon
22
AstraZeneca
AZN
$246B
$12.1M 0.73%
+100,745
New +$11.7M
ANAB icon
23
AnaptysBio
ANAB
$1.71B
$11.8M 0.71%
436,592
– –
PBYI icon
24
Puma Biotechnology
PBYI
$453M
$9.77M 0.59%
1,392,997
– –
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.81B
$8.5M 0.51%
444,900
+43,800
+11% +$730K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q3 2021 Portfolio in Review

As of Q3 2021, Palo Alto Investors held 43 positions worth $1.66B, down 8.7% from $1.81B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 4.7%. Palo Alto Investors opened 1 new position and exited 1, leaving the 43-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q3 2021 buy was AstraZeneca: 100,745 shares worth $12.1M.
  • Palo Alto Investors added most to Dicerna Pharmaceuticals, Inc. in Q3 2021, an estimated $14.4M increase.
  • Palo Alto Investors's biggest Q3 2021 reduction was STAAR Surgical, cutting an estimated $17.8M.
  • Palo Alto Investors fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $17.4M.
  • Palo Alto Investors's ten largest holdings make up 76% of its $1.66B portfolio in Q3 2021.
  • Palo Alto Investors opened 1 new position and closed 1 in Q3 2021.
  • Palo Alto Investors's portfolio value fell 8.7% quarter-over-quarter to $1.66B.

Based on Palo Alto Investors's 13F filing for Q3 2021, filed 15 Nov 2021.